• Subscribe to the AG's RSS Feed
  • Join the AG's FaceBook
  • Follow the AG on Twitter
  • View the AG's YouTube Channel

Attorney General Lockyer Announces Availability of Pharmaceutical Public Education Grants Under Settlement With Warner-Lambert in Neurontin Off-Label Marketing Case

Wednesday, August 31, 2005
Contact: (415) 703-5837, agpressoffice@doj.ca.gov

(SACRAMENTO) – Attorney General Bill Lockyer today announced that up to $14.9 million in grants now are available as part of a 2004 settlement with Warner-Lambert (W-L) that resolved allegations the W-L division of Pfizer, Inc. – the world’s largest pharmaceutical firm – improperly and deceptively marketed “off-label” uses of the blockbuster drug Neurontin.

The May 2004 consumer protection settlement that served as the source of the grant funds was part of a $430 million, global federal and state settlement of the off-label marketing allegations against W-L. The consumer protection share of the global settlement was approximately $40 million, with 75 percent of the money earmarked for either the grant program or a corrective advertising program to provide balanced information to consumers and prescribers about Neurontin and similar drugs.

The grants announced today represent the first phase of a multi-phase funding strategy developed by a “Special Committee” of state Attorneys General that includes Lockyer, Florida Attorney General Charles J. Crist, New York Attorney General Eliot Spitzer, North Carolina Attorney General Roy Cooper, Ohio Attorney General Jim Petro, Oregon Attorney General Hardy Myers, Texas Attorney General Greg Abbott and Vermont Attorney General William H. Sorrell.

Phase One of the strategy focuses on providing pharmaceutical marketing and drug information through educational campaigns that target prescribers and consumers. This phase will include several rounds of funding, with preference given to programs that are national in scope. The goal of the first phase is to better educate consumers and improve health care professionals’ prescribing practices by providing information about the drug-approval process, drug marketing techniques, and sources of impartial and balanced information about drugs.

Proposals can be submitted by individual states, a group of states or other governmental entities. They also can be submitted by academic institutions, as well as nonprofit organizations with current section 501(c)(3) tax status and expertise in health-related or consumer protection issues. Nonprofit organizations must include in their applications written support from the Attorney General of any state in which the organization operates. Requests for Application may be found at www.publichealthtrust.org . The deadline for submitting Phase One grant proposals is October 7, 2005.

Phase Two of the public education campaign will focus on providing information about seizure disorders and psychological conditions for which Neurontin has been prescribed. The details of the second phase will be developed as the program progresses.

The consumer protection investigation focused on alleged violations of state consumer protection laws by W-L in its promotion of Neurontin for various “off-label” indications. It is illegal for pharmaceutical manufacturers to promote off-label uses of their drugs, although doctors are permitted to prescribe drugs for such uses. Neurontin is a prescription medication approved by the U.S. Food and Drug Administration for treatment of epilepsy and post-herpetic neuralgia. Approximately 90 percent of Neurontin prescriptions, however, are for off-label purposes.

# # #
PDF icon 05-073_0a.pdf201.72 KB
PDF icon 05-073_0a.pdf201.72 KB

Press Office Contacts

Email: agpressoffice@doj.ca.gov

Phone Number: (415) 703-5837


Megan's Law

California Registered Sex Offender Database

Search Now

Site Navigation

Translate Website

  • Google™ Translation Disclaimer

This Google™ translation feature is provided for informational purposes only.

The Office of the Attorney General is unable to guarantee the accuracy of this translation and is therefore not liable for any inaccurate information resulting from the translation application tool.

Please consult with a translator for accuracy if you are relying on the translation or are using this site for official business.

If you have any questions please contact:Bilingual Services Program at (916) 324-5482

A copy of this disclaimer can also be found on our Disclaimer page.

Select a Language Below / Seleccione el Idioma Abajo

Close this box or use the [ X ]